Literature DB >> 15252275

Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011.

I Gyertyán1, K Sághy.   

Abstract

Studies investigating the role of the dopamine D3 receptor in the regulation of motor activity of rodents have used several ligands; however, there have been few comparative studies using agonist-antagonist interactions. In the present study, we compared the effects of dopamine D3 antagonists with different levels of selectivity over D2 receptors (nafadotride, U 99194A and SB 277011) on motor activity as well as on agonist-induced hypoactivity, in mice and rats. Horizontal and vertical movements were measured in photocell activity cages. 7-Hydroxy-2-(di-n-propylamino)tetralin (7-OH-DPAT) and PD 128907 were used as dopaminergic agonists. Both dose-dependently inhibited motor activity in mice and vertical activity in rats, while decreasing horizontal activity of rats at doses of 0.01 and 0.1 mg/kg s.c., with no effect (7-OH-DPAT) or stimulation (PD 128907) at the 1 mg/kg dose. In mice habituated to the activity cage, nafadotride (0.1-3 mg/kg i.p.) caused a dose-dependent decrease in motor activity but did not affect the hypomotility evoked by either 7-OH-DPAT (0.1 mg/kg) or PD 128907 (0.1 mg/kg). In habituated rats it had no significant effect on motor activity and was not able to antagonize the hypoactivity caused by PD 128907 (0.1 mg/kg s.c.). U 99194A (5, 10 and 20 mg/kg s.c.) dose-dependently and significantly increased motor activity in mice and inhibited the effects of both agonists. In rats, nafadotride produced considerable motor stimulation and significantly inhibited the PD 128907-induced decrease in horizontal, but not in vertical, activity. SB 277011 (15-45 mg/kg p.o.) significantly increased motor activity in mice and partially blocked the action of 7-OH-DPAT on vertical, but not on horizontal, activity while against PD 128907, its significant inhibitory effect was restricted to a single dose (20 mg/kg). In habituated rats, SB 277011 (13.5, 20 and 30 mg/kg p.o.) exerted no significant effects on motor activity and did not antagonize the hypoactivity caused by PD 128907. Considerable species differences and movement-type differences (horizontal versus vertical) were observed between the effects of the tested dopamine D2/D3 ligands on motor activity in rodents. The antagonists also differed markedly in the robustness of their action. The poorly D3 selective antagonist, nafadotride, had little effect on motor behaviour. The moderately selective U 99194A exerted marked stimulatory effects on motility, and potently inhibited the actions of agonists. SB 277011, a highly selective dopamine D3 receptor antagonist, showed limited ability to influence the motor activity of rodents.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252275     DOI: 10.1097/01.fbp.0000137857.26150.ab

Source DB:  PubMed          Journal:  Behav Pharmacol        ISSN: 0955-8810            Impact factor:   2.293


  12 in total

1.  Discriminative stimulus properties of S32504, a novel D3/D2 receptor agonist and antiparkinson agent, in rats: attenuation by the antipsychotics, aripiprazole, bifeprunox, N-desmethylclozapine, and by selective antagonists at dopamine D2 but not D3 receptors.

Authors:  Mark J Millan; Loretta Iob; Jean-Louis Péglion; Anne Dekeyne
Journal:  Psychopharmacology (Berl)       Date:  2006-09-19       Impact factor: 4.530

2.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: II. behavioural characterisation of RG-15.

Authors:  István Gyertyán; Katalin Sághy; Judit Laszy; Ottilia Elekes; Rita Kedves; Larisza I Gémesi; Gabriella Pásztor; Mária Zájer-Balázs; Margit Kapás; Eva Agai Csongor; György Domány; Béla Kiss; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-12       Impact factor: 3.000

3.  A functional role for the dopamine D3 receptor in the induction and expression of behavioural sensitization to ethanol in mice.

Authors:  Sarah Jane Harrison; José N Nobrega
Journal:  Psychopharmacology (Berl)       Date:  2009-08-07       Impact factor: 4.530

4.  The dopamine D3 receptor is part of a homeostatic pathway regulating ethanol consumption.

Authors:  Jerome Jeanblanc; Dao-Yao He; Nancy N H McGough; Marian L Logrip; Khanhky Phamluong; Patricia H Janak; Dorit Ron
Journal:  J Neurosci       Date:  2006-02-01       Impact factor: 6.167

5.  Sex differences in tolerance to the locomotor depressant effects of lobeline in periadolescent rats.

Authors:  Steven B Harrod; M Lee Van Horn
Journal:  Pharmacol Biochem Behav       Date:  2009-09-17       Impact factor: 3.533

6.  Subnanomolar dopamine D3 receptor antagonism coupled to moderate D2 affinity results in favourable antipsychotic-like activity in rodent models: I. neurochemical characterisation of RG-15.

Authors:  Béla Kiss; István Laszlovszky; Attila Horváth; Zsolt Némethy; Eva Schmidt; Gyula Bugovics; Károly Fazekas; István Gyertyán; Eva Agai-Csongor; György Domány; Zsolt Szombathelyi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-06-13       Impact factor: 3.000

7.  Inhibition of 50-kHz ultrasonic vocalizations by dopamine receptor subtype-selective agonists and antagonists in adult rats.

Authors:  Tina Scardochio; Paul B S Clarke
Journal:  Psychopharmacology (Berl)       Date:  2012-11-29       Impact factor: 4.530

8.  Behavioral and neuropharmacological characterization of nicotine as a conditional stimulus.

Authors:  Jennifer E Murray; Rick A Bevins
Journal:  Eur J Pharmacol       Date:  2007-02-01       Impact factor: 4.432

9.  Dopamine D2/3 receptor antagonism reduces activity-based anorexia.

Authors:  S J Klenotich; E V Ho; M S McMurray; C H Server; S C Dulawa
Journal:  Transl Psychiatry       Date:  2015-08-04       Impact factor: 6.222

10.  Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3/D2 receptor ligand [(11)C]-(+)-PHNO.

Authors:  Ragy R Girgis; Mark Slifstein; Deepak D'Souza; Yih Lee; Antonia Periclou; Parviz Ghahramani; István Laszlovszky; Suresh Durgam; Nika Adham; Nabeel Nabulsi; Yiyun Huang; Richard E Carson; Béla Kiss; Margit Kapás; Anissa Abi-Dargham; Ashok Rakhit
Journal:  Psychopharmacology (Berl)       Date:  2016-08-15       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.